Literature DB >> 23261515

Dopamine but not l-dopa stimulates neural glutathione metabolism. Potential implications for Parkinson's and other dopamine deficiency states.

George F G Allen1, Yasmin Ullah, Iain P Hargreaves, John M Land, Simon J R Heales.   

Abstract

Dopamine is produced first by hydroxylalation of l-tyrosine to l-dihydroxyphenylalanine (l-dopa) and subsequently by the decarboxylation of l-dopa to dopamine catalysed by the enzymes tyrosine hydroxylase and aromatic l-amino acid decarboxylase (AADC) respectively. Reduced glutathione (GSH) acts as a major cellular antioxidant. We have investigated the role of dopamine in the control of GSH homeostasis in brain cells. The SH-SY5Y human neuroblastoma cell line was found to increase intracellular GSH levels in response to 50μM dopamine treatment. Similarly the 1321N1 human astrocytoma cell line was found to increase GSH release in response to 50μM dopamine. The same concentration of l-dopa was also found to increase intracellular GSH in SH-SY5Y cells, however when AADC was inhibited this affect was abolished. Furthermore 1321N1 cells which were found to have almost undetectable levels of AADC activity did not increase GSH release in response to 50μM l-dopa. These results suggest that at these concentrations dopamine has the potential to act as a signal for the upregulation of GSH synthesis within neuronal-like cells and for the increased trafficking of GSH from astrocytes to neurons. This effect could potentially relate to the activation of antioxidant response elements leading to the induction of phase II detoxifying enzymes including those involved in GSH synthesis and release. The inability of l-dopa to produce a similar effect when AADC was inhibited or when AADC activity was absent indicates that these effects are relatively specific to dopamine. Additionally dopamine but not l-dopa treatment led in an increase in complex I activity of the respiratory chain in SH-SY5Y cells which may be related to the effect of dopamine on GSH levels.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23261515     DOI: 10.1016/j.neuint.2012.12.004

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  10 in total

1.  Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.

Authors:  Thomas Müller; Siegfried Muhlack
Journal:  J Neural Transm (Vienna)       Date:  2014-01-05       Impact factor: 3.575

2.  Analysis of human cerebrospinal fluid monoamines and their cofactors by HPLC.

Authors:  Marta Batllori; Marta Molero-Luis; Aida Ormazabal; Mercedes Casado; Cristina Sierra; Angels García-Cazorla; Manju Kurian; Simon Pope; Simon J Heales; Rafael Artuch
Journal:  Nat Protoc       Date:  2017-10-19       Impact factor: 13.491

3.  Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease.

Authors:  Monica Colamartino; Massimo Santoro; Guglielmo Duranti; Stefania Sabatini; Roberta Ceci; Antonella Testa; Luca Padua; Renata Cozzi
Journal:  Neurotox Res       Date:  2014-10-30       Impact factor: 3.911

4.  Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease.

Authors:  Thomas Müller; Isabel Trommer; Siegfried Muhlack; Bernhard K Mueller
Journal:  J Neural Transm (Vienna)       Date:  2016-02-15       Impact factor: 3.575

5.  Molecular Effects of L-dopa Therapy in Parkinson's Disease.

Authors:  Jolanta Dorszewska; Michal Prendecki; Margarita Lianeri; Wojciech Kozubski
Journal:  Curr Genomics       Date:  2014-02       Impact factor: 2.236

6.  The Effects of Fasting During Ramadan on the Concentration of Serotonin, Dopamine, Brain-Derived Neurotrophic Factor and Nerve Growth Factor.

Authors:  Abdolhossein Bastani; Sadegh Rajabi; Fatemeh Kianimarkani
Journal:  Neurol Int       Date:  2017-06-23

7.  Effects of bee venom and dopamine-loaded nanoparticles on reserpine-induced Parkinson's disease rat model.

Authors:  Omar A Ahmed-Farid; Mohamed Taha; Rofanda M Bakeer; Omyma K Radwan; Hassan A M Hendawy; Ayman S Soliman; Einas Yousef
Journal:  Sci Rep       Date:  2021-10-27       Impact factor: 4.379

8.  Pharmacological profile of brain-derived neurotrophic factor (BDNF) splice variant translation using a novel drug screening assay: a "quantitative code".

Authors:  Valentina Vaghi; Alessio Polacchini; Gabriele Baj; Vera L M Pinheiro; Annalisa Vicario; Enrico Tongiorgi
Journal:  J Biol Chem       Date:  2014-07-29       Impact factor: 5.157

Review 9.  Mitochondrial quality control: decommissioning power plants in neurodegenerative diseases.

Authors:  Rukmini Mukherjee; Oishee Chakrabarti
Journal:  ScientificWorldJournal       Date:  2013-10-28

10.  Neuroprotective Role of Astroglia in Parkinson Disease by Reducing Oxidative Stress Through Dopamine-Induced Activation of Pentose-Phosphate Pathway.

Authors:  Kyoko Mashima; Shinichi Takahashi; Kazushi Minami; Yoshikane Izawa; Takato Abe; Naoki Tsukada; Takako Hishiki; Makoto Suematsu; Mayumi Kajimura; Norihiro Suzuki
Journal:  ASN Neuro       Date:  2018 Jan-Dec       Impact factor: 4.146

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.